/

ABVC

ABVC Biopharma, Inc.Closed

0.9790−0.01 −1.07%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 0.9790 0.00%

Open

1.00

Prev close

0.9896

Day range

0.96001.02

52-week range

0.70703.07

Volume

119.96K1.10×

Mkt cap

26.13M

P/E ttm

—

Fwd P/E

-2.23

EPS ttm

-0.3000

Div yield

0.00%

Earnings

—

From 52w high

−68.11%

Price Chart

Yahoo Finance · delayed

ABVCOct 13, 2026O 1.0000H 1.0180L 0.9600C 0.9790−0.0010 (−0.10%)Vol 120.00K

SMA 500.9795
SMA 2001.3359

1Y change −66.93% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

ABVC ABVC Biopharma, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +0.93%
1 month: −0.10%
3 months: −26.94%
6 months: −28.01%
Year to date: −54.04%
1 year: −66.93%

Valuation & ownership

Market cap: 26.13M
Enterprise value: 30.15M
P/E (ttm): —
Forward P/E: -2.23
PEG ratio: —
Price / book: 2.42
Price / sales (ttm): —
EV / EBITDA: -4.64
EPS (ttm): -0.3000
EPS (forward): -0.4400
Beta (5y monthly): 0.51
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 26.69M
Float: 21.10M
Short % of float: 2.24%
Short ratio (days): 3.64
Held by insiders: 18.09%
Held by institutions: 4.08%
Avg volume (3m): 108.84K
50-day average: 0.9807
200-day average: 1.34
52-week change: −66.93%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 44.9
vs 50-day SMA: −0.05%
vs 200-day SMA: −26.71%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 7.91%
Realised vol (20d, ann.): 48.9%
From 52-week high: −68.11%
From 52-week low: +38.47%

ANR

Analyst Consensus

No analyst coverage for this instrument.

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): —
Revenue growth (yoy): —
Earnings growth (yoy): —
Gross margin: 0.00%
Operating margin: 0.00%
Profit margin: 0.00%

DES

About ABVC Biopharma, Inc.

Yahoo Finance profile

ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 16
Headquarters: Fremont, CA, United States
Website: abvcpharma.com
Officers: Mr. Eugene Jiang Chairman & Chief Business Officer
Dr. Uttam Yashwant Patil Ph.D.

SEAS

Seasonality · ABVC

2007–2026 · monthly returns

Strongest month Sep +21921.64%Weakest month Oct −15.79%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-5.2	-35.1	-26.0	6.2	36.9	12.1	-36.1	-15.0	23.5	-7.6			−54.0%
2025	-12.4	33.5	53.6	0.0	29.2	62.4	7.9	17.9	7.4	-7.9	-3.2	-21.4	+261.0%
2024	31.0	-20.4	8.3	-4.6	-36.5	-2.5	0.6	-13.4	1.2	1.2	-23.3	11.3	−49.1%
2023	15.5	-8.0	-3.6	6.3	0.0	-23.5	-52.1	-47.4	-20.6	3.8	16.7	-7.9	−81.4%
2022	-26.3	-0.8	10.1	-12.5	-17.2	-46.5	-38.7	55.4	-12.9	-17.0	1.2	-15.4	−81.6%
2021	-2.0	-12.0	2.3	0.0	22.2	-8.2	-2.2	-41.3	-20.3	10.0	19.7	11.5	−33.5%
2020	-33.6	0.0	-15.5	30.6	-6.3	0.0	31.7	1.3	0.0	-2.5	7.7	21.4	+16.7%
2019	-25.0	-3.3	3.4	-16.7	-4.4	-39.5	-15.4	-25.7	10.2	-41.1	25.5	-34.3	−87.9%
2018	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	5.3	-17.5	0.0	-3.0	25.0	−0.0%
2017	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0%
2016	0.0	0.0	-77.2	10.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	−74.9%
2015	-90.0	100.0	100.0	0.0	0.0	0.0	150.0	-100.0	416566.7	0.0	0.0	0.0	−50.0%
2014	0.0	0.0	0.0	0.0	50.0	0.0	6.7	-37.5	20.0	-33.3	0.0	25.0	+0.0%
2013	300.0	60.0	-12.5	60.7	-62.2	0.0	0.0	-5.9	0.0	0.0	-18.7	-23.1	+100.0%
2012	44.4	-44.6	12.5	2.5	20.5	-40.0	0.0	-66.7	0.0	-55.0	-11.1	-37.5	−94.4%
2011	-20.0	-82.5	0.0	471.4	-50.0	0.0	-20.0	537.5	-70.6	-60.0	150.0	-40.0	−64.0%
2010	-12.5	-14.3	50.0	-37.0	-11.8	-33.3	-30.0	-27.1	37.3	-14.3	-66.7	150.0	−79.2%
2009	28.6	-44.4	20.0	-41.7	42.9	70.0	-17.6	37.1	-42.7	-36.4	14.3	-40.0	−65.7%
2008	-4.8	-41.7	-40.0	0.0	57.1	-23.0	41.7	-65.5	61.0	-20.0	-6.3	-6.7	−77.8%
2007	-24.3	5.7	-10.7	34.0	1.5	55.0	19.4	-25.0	-8.0	-27.5	-20.0	96.9	+41.6%

ABVC

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

ABVC

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About ABVC Biopharma, Inc.

Seasonality · ABVC

Insider Activity · ABVC

Congress Trades · ABVC

Investors Holding ABVC

Investors Holding ABVC

Congress Trades · ABVC

Insider Activity · ABVC

Seasonality · ABVC

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About ABVC Biopharma, Inc.

Earnings & Dividends

News